ARVN 3Q26 Earnings Call - ARVINAS INC

Financial Performance:

• Cash, cash equivalents, restricted cash, and marketable securities totaled $558.9 million at quarter-end 2026 (down from $685.4 million in Q3 2025), with cash runway extending into the second half of 2028.
• Revenue recognized $0.5 million in royalties from the Rigel license agreement; Yale royalty revenue is reported under "cost of license revenue."
• General and Administrative (G&A) expenses fell to $12.6 million from $21.0 million year-over-year (YoY), driven by reductions in personnel, infrastructure, commercial development costs, and professional fees.
• Research and Development (R&D) expenses decreased to $46.9 million from $64.7 million YoY, primarily due to lower program-specific spending, non-program expenses, and compensation costs.
• Non-GAAP expenses totaled $53.5 million, representing a 25% YoY reduction (down $18.0 million), reflecting disciplined capital allocation across the organization.

Guidance and Future Outlook:

• ARV-393 (BCL-6 degrader): Initial monotherapy data presentation scheduled for the ASH conference in December 2026; second data readout expected mid-2027 focusing on B-cell lymphoma and glofitamab combinations.
• ARV-027 (SBMA degrader): Initial data from Healthy Volunteer cohorts to be shared in the first half of 2027; patient dosing planned for the first half of 2027 with discussions regarding registration-enabling trials contingent on Phase 1 success.
• ARV-6723 (HPK1 degrader): Phase 1 monotherapy ongoing; combination dosing with pembrolizumab targeted for the first half of 2027; initial data expected in the second half of 2027.
• ARV-102 (LRRK2 degrader): Clinical trial applications for Phase 1b in PSP to be submitted in Europe/UK next month; trial initiation targeted for 2027; U.S. participation contingent on resolving clinical hold.
• ARV-806 (K-Ras G12D degrader): No further in-house guidance provided; program requires a partner to advance, with data expected at an upcoming conference.

Business Segments and Product Lines:

• Oncology (ARV-393): Oral BCL-6 degrader showing activity in T-cell lymphomas at doses below predicted efficacy; potential to serve as backbone monotherapy or combination therapy to reduce chemotherapy reliance.
• Neurology (ARV-027): First-in-class oral androgen receptor degrader targeting PolyQAR for SBMA; aims for 50% reduction in target protein to rescue muscle strength and endurance.
• Immunology (ARV-6723): Oral HPK1 degrader designed to overcome checkpoint inhibitor resistance; preclinical data shows activity in 7 resistant models and synergy with anti-PD-1.
• Neurology (ARV-102): LRRK2 degrader; biomarker updates show brain penetration, LRRK2 reduction in CSF, and improvements in oculomotor function in Parkinson's patients; moving to Phase 1b in Progressive Supranuclear Palsy (PSP).
• Partnership Strategy: ARV-806 remains a partnered asset only; company will focus capital on Phase 1 programs (ARV-393, ARV-027, ARV-6723, ARV-102) as wholly-owned assets.

Market and Competitive Landscape:

• T-cell lymphomas face significant unmet need with current market response rates of 35-45%; Arvinas aims for >30% response rates in early monotherapy trials.
• Competitors are also targeting BCL-6; early monotherapy data for competitors shows >50% response rates, setting a benchmark for Arvinas to compete in later-stage B-cell indications.
• HPK1 degrader addresses tumor microenvironments where PD-1 and VEGF therapies have limited success, potentially offering benefits in post-checkpoint inhibitor settings.
• SBMA and PSP represent rare, genetically defined diseases with limited existing disease-modifying therapies.

Risks and Challenges:

• ARV-102 Regulatory Hold: Ongoing discussions with the FDA regarding the clinical hold in the U.S.; current plan involves executing Phase 1b in Europe/UK without U.S. sites initially.
• Biomarker Translation: Uncertainty remains regarding the correlation between surrogate biomarkers (e.g., oculomotor function, CSF markers) and long-term clinical disease progression in neurodegenerative trials.
• Dose Optimization: Early ARV-393 data is based on doses below predicted efficacious levels; future data must demonstrate durability and efficacy at higher doses in B-cell lymphomas.
• Capital Allocation: While cash runway is sufficient through 2028 for key milestones, future funding requirements beyond that period remain subject to clinical data outcomes.

Management Commentary and Tone:

• Tone was cautious yet confident, emphasizing a "data-driven" capital allocation strategy and prioritizing high-value programs.
• Leadership highlighted the strategic pivot from "scientific promise" to clinical validation, celebrating the first FDA-approved proteolysis target as a foundation for future successes.
• Management expressed strong belief in the protein degradation platform's ability to address "undruggable" targets and change treatment landscapes across oncology and neurology.
• Emphasis was placed on transparency regarding the ARV-806 partnership requirement and the specific data milestones needed to advance the portfolio.

Analyst Questions and Answers:

• ARV-102 Clinical Hold: Management confirmed the Phase 1b trial will proceed in Europe/UK initially; U.S. patient inclusion depends on future FDA discussions but is expected later in development.
• Yale Royalty Terms: Disclosed as a low single-digit royalty (approx. 1%) on revenue, applicable only to specific programs, not the entire portfolio.
• ARV-027 Degradation Target: Confirmed a goal of 50% reduction in PolyQAR in muscle, based on preclinical rescue of muscle strength and survival.
• ARV-393 ASH Data Expectations: Focused on T-cell patients (mid-teens patient count) to demonstrate proof-of-concept; B-cell data expected mid-2027 with higher doses and durability metrics.
• ARV-6723 Differentiation: Preclinical data supports activity in checkpoint-resistant models; combination with pembrolizumab planned for H1 2027.
• Capital Runway: Explicitly stated that all major programs (BCL-6, SBMA, etc.) are fully funded through key readouts and into 2028.
• PSP Biomarkers: Shifted focus from oculomotor tracking (used in PD) to movement and falling endpoints, while still studying tau reduction and synaptic markers like neurofilament light chain.

Other Key Points:

• ARV-393 is the first BCL-6 degrader in the clinic for T-cell lymphomas, a population with no approved therapies.
• ARV-027 targets both wild-type and mutant androgen receptors, but in SBMA patients (X-linked), only the mutant form exists, simplifying the safety profile regarding wild-type degradation.
• The company reported preclinical data on ARV-6723 at the Society for Immunotherapy of Cancer Annual Meeting, highlighting immune system remodeling beyond T-cell activation.
• Management reiterated the intent to let clinical data dictate future investment, maintaining a lean operational structure with significant cost reductions compared to the prior year.